ReviewMedical oncology (Northwood, London, England)2025
PLIN3: a multifaceted regulator of lipid droplet dynamics and disease pathogenesis.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lipids, as core membrane components, energy stores, and signaling molecules, are indispensable for homeostasis; their dysregulation drives obesity, type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). Lipid droplets (LDs), originating from the endoplasmic reticulum, are phospholipid-monolayer-enclosed organelles that dynamically interact with mitochondria and peroxisomes, buffering lipotoxicity, sequestering bioactive lipids, and facilitating enzymatic reactions-positioning them as metabolic hubs. PLIN3, a PAT family protein, uniquely regulates LD formation/stabilization andmediates mannose 6-phosphate receptor (MRP) trafficking: its dysfunction links to cancer (amplified growth factor receptor recycling), neurodegeneration (impaired α-synuclein clearance), and metabolic syndrome (hepatic cholesterol retention). This review synthesizes PLIN3's structural features, LD-centric roles, and non-canonical MRP transport, establishing it as a critical node bridging lipid homeostasis and disease, with implications for therapeutic targeting in metabolic, oncologic, and neurodegenerative conditions.
Indexed as
Identifiers
41441956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.